EUVIMEDEUVIMED entdecken
Open Access

The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage

Georgios Efthymiou iD, Eugénie Lohmann iD, Claudio Montenegro iD, Paraskevi Kousteridou iD, Pierre Bertrand iD, Julia Pereira iD, Heather S Carr, Issam Ben-Sahra iD, Coralie Compare, Ivan Nemazanyy iD, Ghislain Bidaut iD, Pascal Finetti iD und 5 weitere

Science Advances · 12.12.2025 · 11 (50)

DOI: 10.1126/sciadv.adu2276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 12.12.2025. Verfasst von Georgios Efthymiou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France. Hauptthemen laut MEDLINE: Oxaliplatin, Extracellular Matrix, DNA Damage, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fondation pour la Recherche Médicale, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The excessive production of extracellular matrix (ECM) and the metabolic adaptations in pancreatic ductal adenocarcinoma (PDAC) contribute individually to enhanced chemoresistance, marked tumor progression, and dismal patient survival. However, ECM-driven metabolic alterations that promote chemoresistance in PDAC are so far unexplored. Here, we use in vitro–generated ECM bioscaffolds that recapitulate cell-ECM interactions and induce broad metabolic alterations in PDAC cells. High-throughput integration of multiomics datasets coupled with metabolic tracing showed that the ECM enhances the generation of guanylates in PDAC cells, the accumulation of which alleviates oxaliplatin-induced DNA damage, and boosts PDAC cell proliferation. These events are guided by the guanosine monophosphate (GMP)–producing enzymes inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthase (GMPS), the expression of which correlated with that of matrisomal and DNA repair genes in samples from patients with PDAC. We propose that targeting ECM-driven metabolic processes, such as the enhanced IMPDH activity, may be an effective therapeutic approach for patients with PDAC to bypass the negative side effects of direct targeting of the ECM itself.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinExtracellular MatrixDNA DamagePancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansCell Line, TumorCell ProliferationAntineoplastic AgentsIMP DehydrogenaseDrug Resistance, Neoplasm

Substanzen

OxaliplatinAntineoplastic AgentsIMP Dehydrogenase

Autor:innen und Institutionen

  • Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France.
  • Research Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Recife, 50670-901 PE, Brazil.
  • Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Platform for Metabolic Analyses, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR 3633, Paris, France.

ORCID-Profile: Georgios Efthymiou, Eugénie Lohmann, Claudio Montenegro, Paraskevi Kousteridou, Pierre Bertrand, Julia Pereira, Issam Ben-Sahra, Ivan Nemazanyy, Ghislain Bidaut, Pascal Finetti, François Bertucci, Christophe Lachaud, Richard Tomasini, Sophie Vasseur

Förderung

  • Fondation pour la Recherche Médicale
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fondation ARC pour la Recherche sur le Cancer
  • Institut National Du Cancer
  • Cancéropôle Provence-Alpes-Côte d’Azur
  • Région Sud & Canceropôle Provence-Alpes-Côte d’Azur
  • Association Française pour la Recherche sur le Cancer du 1126 Pancréas
  • National League Against Cancer

Zitieren

APA

Efthymiou, G., Lohmann, E., Montenegro, C., Kousteridou, P., Bertrand, P., Pereira, J., Carr, H. S., Ben-Sahra, I., Compare, C., Nemazanyy, I., Bidaut, G., Finetti, P., Bertucci, F., Lachaud, C., Guillaumond, F., Tomasini, R., & Vasseur, S. (2025). The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Science Advances, 11(50). https://doi.org/10.1126/sciadv.adu2276

Vancouver

Efthymiou G, Lohmann E, Montenegro C, Kousteridou P, Bertrand P, Pereira J, et al. The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Science Advances. 2025;11(50). doi:10.1126/sciadv.adu2276

BibTeX
@article{Efthymiou2025,
  author = {Efthymiou, Georgios and Lohmann, Eugénie and Montenegro, Claudio and Kousteridou, Paraskevi and Bertrand, Pierre and Pereira, Julia and Carr, Heather S and Ben-Sahra, Issam and Compare, Coralie and Nemazanyy, Ivan and Bidaut, Ghislain and Finetti, Pascal and Bertucci, François and Lachaud, Christophe and Guillaumond, Fabienne and Tomasini, Richard and Vasseur, Sophie},
  title = {The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {50},
  doi = {10.1126/sciadv.adu2276}
}
Kostenlos starten →